Ruconest: a new option for the treatment of angioedema

Ruconest (conestat alfa) is a C1-esterase inhibitor analogue and is licensed for the treatment of acute attacks of hereditary angioedema type I or II.

Conestat alfa is produced from transgenic rabbits rather than being derived from human plasma
Conestat alfa is produced from transgenic rabbits rather than being derived from human plasma

PHARMACOLOGY

Conestat alfa is a recombinant human complement component 1 (C1) esterase inhibitor obtained from rabbits.

CLINICAL STUDIES

In 2 double-blind studies, 70 patients with hereditary angioedema due to C1-esterase inhibitor  deficiency were randomised to receive conestat alfa 100 units/kg, 50 units/kg or placebo at the onset of an attack. In the pooled analysis, median time to beginning of symptom relief was significantly reduced in both treatment arms compared with placebo (66 minutes and 122 minutes vs 495 minutes, p<0.001 and p=0.013, respectively). Additionally, the median time to minimal symptoms was also significantly shorter in those receiving either 100 units/kg or 50 units/kg of conestat alfa compared with placebo (266 minutes and 247 minutes vs 1210 minutes, p<0.001 and p=0.001, respectively).

View Ruconest drug record

Further information: Swedish Orphan Biovitrum Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...